UT Health San Antonio
Olaparib confers durable benefit in BRCA-mutated breast cancer
SAN ANTONIO — One year of adjuvant olaparib after standard treatment improved outcomes compared with placebo among patients with high-risk BRCA-mutated breast cancer, according to data presented at San Antonio Breast Cancer Symposium.
Imlunestrant alone, with abemaciclib delays progression of advanced breast cancer
SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.
Drug shows ‘very promising’ activity in breast cancer brain metastases
Sacituzumab govitecan-hziy exhibited efficacy as therapy for two traditionally difficult-to-treat populations, according to results of a window-of-opportunity trial.
Robotic-assisted THA may be linked with increased costs, risk of periprosthetic fracture
Published results showed robotic-assisted total hip arthroplasty was associated with increased total patient charges and risk of surgical complications, such as periprosthetic fractures and transfusions, compared with conventional THA.
Semaglutide may be an effective weight loss supplement for obese patients undergoing THA
SAN FRANCISCO — Results showed patients who were obese preoperatively and were treated with semaglutide, an anti-obesity medication, had similar outcomes and complications after total hip arthroplasty vs. those who did not receive the drug.
Patients with depression may have increased rates of complications after TKA
SAN FRANCISCO — Results presented here showed patients with depression undergoing total knee arthroplasty experienced an increased risk of medical and surgical complications, readmissions and reoperations.
CATALYST: Hypercortisolism prevalence high with difficult-to-treat type 2 diabetes
Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release.
Boris A. Zelle, MD, FAAOS, FAOA, accepts AAOS Diversity Award
Boris A. Zelle, MD, FAAOS, FAOA, was presented the 2024 American Academy of Orthopaedic Surgeons Diversity Award, according to a press release.
Mammography data are ‘practice-changing’ in US for older women with breast cancer
SAN ANTONIO — Women aged 50 years or older who de-escalated to less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography.
Findings may help resolve ‘active debate’ about adjuvant radiotherapy for breast cancer
SAN ANTONIO — Treatment de-escalation may be possible for patients with breast cancer who respond well to neoadjuvant chemotherapy, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.